comparemela.com

Latest Breaking News On - Vicore pharma holding ab - Page 1 : comparemela.com

Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),.

United statesNew zealandHong kongUnited kingdomSouth africaVan lanschot kempenCarl johan dalsgaardNeither the companyFourth swedish national pension fundPrnewswire vicore pharma holdingBaker mckenzieFinancial servicesCarnegie investment bankEuropean union withdrawalVicore pharma holdingCommission delegated directive

Vicore intends to carry out a directed share issue

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),.

United statesNew zealandHong kongUnited kingdomSouth africaVan lanschot kempenCarl johan dalsgaardNeither the companyBaker mckenzieFinancial servicesCarnegie investment bankEuropean union withdrawalVicore pharma holdingCommission delegated directivePareto securitiesZonda partners

Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), today launched.

United statesNational jewish healthJessica shullCarl johan dalsgaardVicore pharma holdingCognitive behavioral therapyJosh solomonDigital therapeuticsJohan dalsgaardAlex therapeuticsPharma holdingVicore pharma holding ab

Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),.

United statesMichael kreuterTamera corteToby maherKevin flahertyCarl johan dalsgaardDepartment of internal medicinePrnewswire vicore pharma holdingDivision of pulmonary critical care medicineVicore pharma holdingUniversity of michiganProfessor toby maherKeck schoolSouthern californiaProfessors kevin flahertyCritical care medicine

Vicore s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study

/PRNewswire/ Vicore Pharma Holding AB (publ) ( Vicore ) pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces positive.

Vastra gotalands lanJessica shullMaureen hortonCarl johan dalsgaardDivision of pulmonaryVicore pharma holdingJohns hopkins university school of medicineCognitive behavioral therapyPrincipal investigatorCritical care medicineJohns hopkins university schoolJohns hopkins interstitial lung diseaseDigital therapeuticsJohan dalsgaardAlex therapeuticsPharma holding

vimarsana © 2020. All Rights Reserved.